R. Linde

2.9k total citations · 1 hit paper
44 papers, 1.4k citations indexed

About

R. Linde is a scholar working on Infectious Diseases, Virology and Hematology. According to data from OpenAlex, R. Linde has authored 44 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 11 papers in Virology and 11 papers in Hematology. Recurrent topics in R. Linde's work include HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (9 papers) and Platelet Disorders and Treatments (7 papers). R. Linde is often cited by papers focused on HIV Research and Treatment (11 papers), HIV/AIDS drug development and treatment (9 papers) and Platelet Disorders and Treatments (7 papers). R. Linde collaborates with scholars based in Germany, United States and Poland. R. Linde's co-authors include W. Kreuz, Markus B. Funk, I. Scharrer, Tayfun Güngör, B. Kornhuber, B. Krackhardt, S. Ehrenforth, Gerald A. Galvin, Howard W. Jones and Lawrence R. Wharton and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Blood.

In The Last Decade

R. Linde

43 papers receiving 1.3k citations

Hit Papers

Incidence of development of factor VIII and factor IX inh... 1992 2026 2003 2014 1992 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Linde Germany 19 584 263 224 195 171 44 1.4k
R Henrion France 14 53 0.1× 268 1.0× 218 1.0× 54 0.3× 107 0.6× 89 768
Salvatrice Mancuso Italy 19 193 0.3× 198 0.8× 23 0.1× 57 0.3× 84 0.5× 71 1.1k
Ute Hasiba United States 18 786 1.3× 90 0.3× 74 0.3× 18 0.1× 154 0.9× 35 1.5k
Chanane Wanapirak Thailand 22 395 0.7× 458 1.7× 16 0.1× 440 2.3× 40 0.2× 122 2.0k
L. Blum France 16 118 0.2× 335 1.3× 114 0.5× 25 0.1× 111 0.6× 53 1.1k
Gérard Michel France 26 532 0.9× 117 0.4× 41 0.2× 21 0.1× 311 1.8× 77 1.8k
Catherine Donner Belgium 23 140 0.2× 414 1.6× 57 0.3× 601 3.1× 1.0k 6.1× 80 2.7k
Martin A. Ivarsson Sweden 24 231 0.4× 174 0.7× 112 0.5× 240 1.2× 2.4k 14.1× 30 2.7k
M Capella‐Pavlovsky France 7 356 0.6× 282 1.1× 51 0.2× 129 0.7× 54 0.3× 15 1.2k
Juan A. De León-Luis Spain 21 47 0.1× 265 1.0× 176 0.8× 503 2.6× 215 1.3× 163 1.7k

Countries citing papers authored by R. Linde

Since Specialization
Citations

This map shows the geographic impact of R. Linde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Linde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Linde more than expected).

Fields of papers citing papers by R. Linde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Linde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Linde. The network helps show where R. Linde may publish in the future.

Co-authorship network of co-authors of R. Linde

This figure shows the co-authorship network connecting the top 25 collaborators of R. Linde. A scholar is included among the top collaborators of R. Linde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Linde. R. Linde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Neubert, Jennifer, Tim Niehues, Ulrich Baumann, et al.. (2012). Leitlinie der Pädiatrische Arbeitsgemeinschaft AIDS (PAAD) e.V. zur antiretroviralen Therapie bei HIV-infizierten Kindern und Jugendlichen (2011). Klinische Pädiatrie. 224(2). 98–110. 3 indexed citations
2.
Linde, R., et al.. (2009). Inhibitor treatment by rituximabin congenital haemophilia A. Hämostaseologie. 29(2). 151–154. 14 indexed citations
3.
Kessel, Christoph, Christoph Königs, R. Linde, et al.. (2008). Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Molecular Immunology. 46(1). 8–15. 20 indexed citations
4.
Linde, R., et al.. (2006). Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome. European Journal of Pediatrics. 165(5). 348–350. 5 indexed citations
5.
Linde, R., et al.. (2006). Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.. PubMed. 11(9). 377–80. 24 indexed citations
6.
Funk, Markus B., Gundula Notheis, Tobias Schuster, et al.. (2005). Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.. PubMed. 10(12). 503–8. 12 indexed citations
7.
Königs, Christoph, Christoph Kessel, R. Linde, Thomas Klingebiel, & W. Kreuz. (2004). Epitope Mapping during FVIII Inhibitor Elimination with Rituximab Revealed Conformational Epitopes on FVIII and Identifies Potentially Small Molecules for Novel Therapies.. Blood. 104(11). 3081–3081.
8.
Böhler, Thomas, Uwe Wintergerst, R. Linde, Bernd H. Belohradsky, & Klaus‐Michael Debatin. (2001). CD95 (APO-1/Fas) Expression on Naive CD4+ T Cells Increases with Disease Progression in HIV-Infected Children and Adolescents: Effect of Highly Active Antiretroviral Therapy (HAART). Pediatric Research. 49(1). 101–110. 9 indexed citations
9.
Linde, R., Markus B. Funk, Tobias Schuster, et al.. (2001). Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy. AIDS. 15(8). 1077–1079. 4 indexed citations
10.
Böhler, Thomas, et al.. (1999). Expression of CD69 on T-cells from HIV-1-infected children and adolescents increases with increasing viral load. European Journal of Pediatrics. 158(8). 638–644. 10 indexed citations
12.
Becker, Martina, et al.. (1997). Pappataci-Fieber. Klinische Pädiatrie. 209(6). 377–379. 15 indexed citations
13.
Kreuz, W., R. Linde, Markus B. Funk, et al.. (1992). Valproate Therapy Induces von Willebrand Disease Type I. Epilepsia. 33(1). 178–184. 59 indexed citations
14.
Nowak‐Göttl, Ulrike, et al.. (1992). Nichtparametrischer Normalbereich für thrombozytäre Parameter im Kindesalter. Klinische Pädiatrie. 204(1). 37–42. 1 indexed citations
15.
Cichutek, Klaus, S. Norley, R. Linde, et al.. (1992). Development of a quasispecies of human immunodeficiency virus type 1 in vivo.. Proceedings of the National Academy of Sciences. 89(16). 7365–7369. 71 indexed citations
16.
Ehrenforth, S., W. Kreuz, R. Linde, et al.. (1992). Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. The Lancet. 339(8793). 594–598. 471 indexed citations breakdown →
17.
Cichutek, Klaus, Stephen Norley, R. Linde, et al.. (1991). Lack of HIV-1 V3 region sequence diversity in two haemophiliac patients infected with a putative biologic clone of HIV-1. AIDS. 5(10). 1185–1188. 21 indexed citations
18.
Linde, R., Gerald A. Galvin, & Howard W. Jones. (1957). Therapy of carcinoma in situ. American Journal of Obstetrics and Gynecology. 74(4). 792–803. 31 indexed citations
19.
Linde, R., et al.. (1954). Intra-abdominal rupture of pelvic abscesses. American Journal of Obstetrics and Gynecology. 68(1). 402–409. 27 indexed citations
20.
Scott, Roger B., R. Linde, & Lawrence R. Wharton. (1953). Further Studies on Experimental Endometriosis. American Journal of Obstetrics and Gynecology. 66(5). 1082–1103. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026